Acer Therapeutics logo
Acer Therapeutics ACER

Quarterly report 2023-Q3
added 11-20-2023

report update icon

Acer Therapeutics Cash Flow 2011-2026 | ACER

Annual Cash Flow Acer Therapeutics

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-30.3 M -135 K -17 M -29.5 M -16.6 M -14.1 M - - - -6.13 M -8.92 M -4.99 M

Depreciation & Amortization

66 K 70.9 K 70.8 K 58.3 K 27.7 K 4 K 238 K 351 K 388 K 336 K 304 K 210 K

Accounts Payables

3.81 M 1.41 M 1.67 M 561 K 1.03 M 95.9 K 378 K 740 K 702 K 696 K 412 K 476 K

All numbers in USD currency

Quarterly Cash Flow Acer Therapeutics

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - -9.02 M - -22 M -12.9 M -3.01 M - 1.29 M 9.24 M 3.01 M - -13.1 M -8.7 M -5.07 M - -25.5 M -18.1 M -9.75 M - -12 M -7.25 M -3.23 M - -9.89 M -4.76 M - - - - - - - - - - - - - - - - 3.04 M - -7.31 M -5.07 M -2.19 M - -3.47 M -2.35 M -791 K

Depreciation & Amortization

- - 15.5 K - 52.8 K 38.8 K 20.6 K - 51.2 K 32.6 K 14.6 K - 53.1 K 35.4 K 17.7 K - 40.6 K 27.1 K 9.55 K - 16.6 K 11 K 6.22 K - 2.71 K - - - 52 K 65.7 K 72.6 K - 89 K 94 K 97 K - 97.4 K 98.7 K 95.6 K - 90.9 K 88.9 K 78.3 K - 81.5 K 76.5 K 67.4 K - 56.9 K 70.7 K 29.6 K

Accounts Payables

7.01 M 5.71 M 1.6 M 3.81 M 4.69 M 3.49 M 2.02 M 1.41 M 1.09 M 1.81 M 429 K 1.67 M 1.67 M 1.67 M 1.67 M 561 K 561 K 561 K 561 K 1.03 M 1.03 M 1.03 M 1.03 M 95.9 K 95.9 K 95.9 K 95.9 K 383 K 383 K 378 K 378 K 740 K 740 K 740 K 740 K 702 K 702 K 702 K 702 K 696 K 696 K 696 K 696 K 412 K 412 K 412 K 412 K 491 K 476 K 476 K 476 K

Accounts Receivables

- - - - - - - - - - 10 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Inventories

5.2 M 4.6 M 412 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Acer Therapeutics, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Alector Alector
ALEC
$ 2.08 -14.4 % $ 214 M usaUSA
Altimmune Altimmune
ALT
$ 4.2 -2.67 % $ 298 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 20.24 -3.44 % $ 2.55 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.8 1.87 % $ 4.36 M chinaChina
Aprea Therapeutics Aprea Therapeutics
APRE
$ 0.88 -3.72 % $ 3.18 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 7.2 -1.64 % $ 1.99 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.1 2.37 % $ 356 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.35 1.46 % $ 225 M israelIsrael
Ardelyx Ardelyx
ARDX
$ 6.37 -2.75 % $ 1.54 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
argenx SE argenx SE
ARGX
$ 756.71 -1.33 % $ 25 B niderlandNiderland
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 10.91 1.58 % $ 394 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 25.33 -6.1 % $ 3.22 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Artelo Biosciences Artelo Biosciences
ARTL
$ 1.15 -3.36 % $ 2.32 M usaUSA
Arvinas Arvinas
ARVN
$ 12.97 -2.3 % $ 920 M usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 61.74 -2.42 % $ 8.26 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 231.56 -0.83 % $ 5 B danmarkDanmark
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.39 -1.63 % $ 8.16 B australiaAustralia
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.17 -0.85 % $ 35.2 M usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
$ 4.39 -0.9 % $ 553 M usaUSA
Atara Biotherapeutics Atara Biotherapeutics
ATRA
$ 5.01 -7.47 % $ 37.5 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 14.14 -0.21 % $ 1.9 B canadaCanada
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.68 -1.75 % $ 429 M britainBritain
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 4.69 0.21 % $ 395 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 4.54 2.44 % $ 387 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 570.5 5.18 % $ 43.2 B usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 162.28 -0.98 % $ 8.07 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.56 -0.58 % $ 16.1 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA